(NASDAQ:TGTX) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share.
Related Questions
How will the completed $100 million buyback affect TG Therapeutics’ short‑term liquidity and valuation metrics?
What does the initiation of a new $100 million repurchase program signal about management’s confidence and how does it compare to peer buyback activity in the biotech sector?
Is the timing of the repurchase aligned with expected earnings releases or catalyst events that could amplify the stock’s momentum?